Short News


short news

Prof. Haroon Hamid selected
for Wasti Gold Medal

LAHORE: Prof. Haroon Hamid General Secretary of Pakistan Paediatric Association Punjab has been selected for Wasti Memorial Gold Medal. It may be mentioned here that Wasti Memorial Medal is awarded by Pakistan Paediatric Association every two years to pediatricians for their outstanding contributions in this specialty.

In the past those who have earned this Wasti Memorial Medal include Prof. Suleman Malik, Prof. Saeedul Haq, Prof. Tahir Masood, Prof. Munir Saleemi, Prof. Waqar Hussain and Prof. Masood Sadiq.

New information for women
faced with infertility

A new Journal of Obstetrics and Gynaecology Research study offers infertile women new information regarding their expected probabilities of becoming pregnant and may help them select the optimal treatment based on their various risk factors.

In an analysis of the medical records of 1,864 female infertile patients in Tokyo from 2000-2015, 49.4% and 21.9% of patients conceived after being treated with assisted reproductive technology (ART) and non-ART, respectively. Age over 35 years, advanced endometriosis, and a past history or current presence of uterine fibroids had negative impacts on the outcome of non-ART. The effect of advanced endometriosis was especially high for patients in their 30s. ART treatment for patients with advanced endometriosis was effective.

ART treatments include in vitro fertilization and intracytoplasmic sperm injection, while non-ART treatments include mild ovarian stimulation together with timed intercourse and/or intra-uterine insemination.Some women in their early 30’s may be suffering from advanced stage endometriosis and will remain to be infertile unless they are extensively treated, said co-author Dr. Osamu Wada-Hiraike, of The University of Tokyo.

What treatable traits predict
future Asthma Attacks?

Investigators have assessed the prevalence of treatable traits in severe asthma and have determined which specific traits are predictive of future asthma attacks. Their findings, which are published in Respirology, are the result of an extensive national collaborative study in Australia.

Ten traits predicted future asthma attacks, and the strongest were: being prone to exacerbations, depression, inhaler device polypharmacy, vocal cord dysfunction, and obstructive sleep apnoea. The findings may help clinicians develop individualized management strategies for patients with severe asthma.

We report the higher burden experienced by patients with severe asthma compared to non-severe and importantly identify which treatable traits are predictive of future asthma attacks. This highlights the usefulness of the treatable traits approach in severe asthma and identifies important targets for treatment, said lead author Dr. Vanessa McDonald, of the University of Newcastle.

Courtesy: Willy Research.

 Novel inhibitor of vascular calcification tested
in clinical trial of haemodialysis patients

Cardiovascular calcification is a major health concern in patients with kidney failure undergoing haemodialysis. A first-time-in-human clinical trial of an investigational calcification inhibitor has generated promising results in terms of safety, tolerability, and pharmacokinetics. The findings are published in the British Journal of Clinical Pharmacology.

The drug, called SNF472, is being studied in additional clinical trials, using various doses and dosing schedules. A phase 1b study was completed in 2016, evaluating the safety, tolerability, and pharmacokinetic and pharmacodynamic activity of SNF472 at repeated dosing in haemodialysis patients. A phase 2 proof of concept study in calciphylaxis patients undergoing haemodialysis was successfully finalized in early 2018, suggesting a positive effect of SNF472 on wound healing and pain in this very ill patient population. A 270-patient, phase 2b, randomized, placebo-controlled study is evaluating the effect of SNF472 in attenuating cardiovascular calcification over 1 year in haemodialysis patients.

We are very proud of this first-in-human trial, which reveals a linear and predictable pharmacokinetic behavior and strengthens the excellent safety profile of SNF472, said senior author Dr. Carolina Salcedo, of Laboratoris Sanifit, in Spain.

This study is just the first step of an ambitious clinical development program with SNF472 to address severe unmet medical needs in patients who suffer from the devastating consequences of accelerated cardiovascular calcification. We are hopeful that in the near future this experimental drug will be available to calciphylaxis and haemodialysis patients, added senior author Dr. Joan Perelló, also of Laboratoris Sanifit.

© Professional Medical Publications. All rights reserved.